Cervical Cancer Diagnosis

Overview

Cervical Cancer diagnosis is the clinical process of detecting and confirming malignant or premalignant changes in the cervix, the lower portion of the uterus that connects to the vagina. Because early disease is often asymptomatic, diagnosis depends heavily on screening, which aims to identify abnormal cells before invasive cancer develops. Cytological examination through the Papanicolaou (Pap) smear detects cellular abnormalities, while testing for high-risk human papillomavirus (HPV) identifies the principal causative agent and refines risk assessment, reflecting the central role of HPV in cervical carcinogenesis. Abnormal screening results are followed by colposcopy and biopsy, which provide the histopathological confirmation required to establish diagnosis, grade precancerous lesions, and determine the depth and extent of invasive disease. Diagnostic evaluation may also incorporate imaging and molecular characterization, including analysis of signaling pathways such as PI3K/AKT/mTOR that are activated in some cervical tumors and may inform prognosis. Screening uptake and access vary considerably across populations and settings, and improving participation among women in diverse communities remains a major determinant of timely detection. Differential diagnosis must also account for benign and inflammatory conditions that can produce abnormal cervical or vaginal cytology. Research in this area addresses screening strategies, HPV-based detection, the molecular features of cervical tumors, and the barriers and facilitators that shape early diagnosis and subsequent treatment outcomes.

Research published in this journal

7 peer-reviewed articles, ranked by relevance. Each links to its DOI.

This page summarises published research for orientation; it is not medical or professional advice.

Related topics